Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00732303 · ClinicalTrials.gov registry record · Phase 2
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Hoosier Cancer Research Network.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00732303 is a Phase 2 study that was terminated before completion, run by Hoosier Cancer Research Network. The registered enrollment target is 8 participants.
The verdict
NCT00732303, a Phase 2 study, was terminated before completion, sponsored by Hoosier Cancer Research Network.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
Pemetrexed is approved for second line therapy in metastatic NSCLC. Given the single-agent activity of pemetrexed and the tolerability of pemetrexed in combination with radiation, this study will evaluate survival rates and toxicities in patients with poor risk stage III NSCLC.
Interventions
- DRUG Pemetrexed
- RADIATION Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2009-01 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00732303
The ClinicalTrials.gov registry entry for NCT00732303 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoosier Cancer Research Network, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pemetrexed is the first listed.
NCT00732303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00732303 about?
NCT00732303 is a clinical study titled "Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer". Pemetrexed is approved for second line therapy in metastatic NSCLC. Given the single-agent activity of pemetrexed and the tolerability of pemetrexed in combination with radiation, this study will evaluate survival rates and toxicities in patients with poor risk stage III NSCLC.
What is the current status of trial NCT00732303?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2009-01. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00732303?
The interventions under investigation include: Pemetrexed (DRUG), Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT00732303?
This trial is sponsored by Hoosier Cancer Research Network, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.